{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:50:09Z","timestamp":1792457409572,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.autrev.2021.102993","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T02:02:24Z","timestamp":1637028144000},"page":"102993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge"],"prefix":"10.1016","volume":"21","author":[{"given":"Gioia","family":"Merlonghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102993_bb0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1756285608097463","article-title":"Review: therapeutic advances and future prospects in immune-mediated inflammatory myopathies","volume":"1","author":"Dalakas","year":"2008","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2021.102993_bb0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102993_bb0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102993_bb0020","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.nmd.2013.07.007","article-title":"193rd ENMC international workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November \u2013 2 December 2012, Naarden, the Netherlands","volume":"23","author":"De Bleecker","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2021.102993_bb0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/joim.12524","article-title":"Diagnosis and classification of idiopathic inflammatory myopathies","volume":"280","author":"Lundberg","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2021.102993_bb0030","doi-asserted-by":"crossref","first-page":"102498","DOI":"10.1016\/j.autrev.2020.102498","article-title":"Muscle involvement in myasthenia gravis: expanding the clinical spectrum of myasthenia-myositis association from a large cohort of patients","author":"Garibaldi","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102993_bb0035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.autrev.2017.05.003","article-title":"Integrated diagnosis project for inflammatory myopathies: an association between autoantibodies and muscle pathology","volume":"16","author":"Suzuki","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102993_bb0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00415-003-1027-y","article-title":"Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy","volume":"250","author":"Bronner","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2021.102993_bb0045","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1212\/WNL.41.6.936","article-title":"Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration","volume":"41","author":"Emslie-Smith","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102993_bb0050","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102993_bb0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2021.102993_bb0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mus.20693","article-title":"Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology","volume":"35","author":"Dimitri","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2021.102993_bb0065","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102993_bb0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","article-title":"Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy","volume":"50","author":"Kao","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102993_bb0075","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2021.102993_bb0080","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102993_bb0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2021.102993_bb0090","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000124","article-title":"Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology","volume":"2","author":"Alshehri","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2021.102993_bb0095","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.autrev.2013.07.001","article-title":"Statin-induced necrotizing myositis - a discrete autoimmune entity within the \u201cstatin-induced myopathy spectrum.\u201d","volume":"12","author":"Hamann","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102993_bb0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102993_bb0105","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/ken325","article-title":"Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies","volume":"47","author":"Suzuki","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102993_bb0110","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2021.102993_bb0115","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102993_bb0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102993_bb0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2021.102993_bb0130","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2021.102993_bb0135","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WCO.0000000000000855","article-title":"Where are we moving in the classification of idiopathic inflammatory myopathies?","volume":"33","author":"Tanboon","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2021.102993_bb0140","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","article-title":"Human autoantibodies reactive with the signal-recognition particle","volume":"83","author":"Reeves","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2021.102993_bb0145","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2021.102993_bb0150","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/archneurol.2011.1728","article-title":"Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome","volume":"69","author":"Suzuki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2021.102993_bb0155","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0b013e32834b324b","article-title":"Necrotizing autoimmune myopathy","volume":"23","author":"Liang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102993_bb0160","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102993_bb0165","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","article-title":"Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile","volume":"181","author":"Preu\u00dfe","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2021.102993_bb0170","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2990.2012.01302.x","article-title":"Review: immune-mediated necrotizing myopathies - a heterogeneous group of diseases with specific myopathological features: immune mediated necrotizing myopathies","volume":"38","author":"Stenzel","year":"2012","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2021.102993_bb0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bpa.12772","article-title":"Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies","volume":"30","author":"Fischer","year":"2020","journal-title":"Brain Pathol"},{"key":"10.1016\/j.autrev.2021.102993_bb0180","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP + and anti-HMGCR + myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102993_bb0185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/s10165-008-0139-8","article-title":"Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies","volume":"19","author":"Takada","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102993_bb0190","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.nmd.2014.01.002","article-title":"Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients","volume":"24","author":"Wang","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2021.102993_bb0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy","volume":"52","author":"Chung","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2021.102993_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jocn.2018.08.010","article-title":"Statin-na\u00efve anti-HMGCR antibody-mediated necrotizing myopathy in China","volume":"57","author":"Jiao","year":"2018","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.autrev.2021.102993_bb0205","series-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","first-page":"10","author":"Meyer","year":"2020"},{"key":"10.1016\/j.autrev.2021.102993_bb0210","series-title":"Immune-mediated necrotizing myopathy due to statins exposure","first-page":"6","author":"Villa","year":"2021"},{"key":"10.1016\/j.autrev.2021.102993_bb0215","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000416","article-title":"Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies: an observational study in Japan","volume":"94","author":"Watanabe","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2021.102993_bb0220","doi-asserted-by":"crossref","first-page":"351","DOI":"10.55563\/clinexprheumatol\/6mp37n","article-title":"Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies","volume":"39","author":"Milisenda","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102993_bb0225","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nan.12519","article-title":"Diagnostic potential of sarcoplasmic myxovirus resistance protein a expression in subsets of dermatomyositis","volume":"45","author":"Uruha","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2021.102993_bb0230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MxA expression: a valuable marker of dermatomyositis","volume":"88","author":"Uruha","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102993_bb0235","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2021.102993_bb0240","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","article-title":"Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy","volume":"2","author":"Aouizerate","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.autrev.2021.102993_bb0245","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2249.1994.tb06032.x","article-title":"MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies","volume":"95","author":"Bartoccioni","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2021.102993_bb0250","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00401-009-0570-8","article-title":"Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities?","volume":"118","author":"Brunn","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.autrev.2021.102993_bb0255","doi-asserted-by":"crossref","first-page":"e1416","DOI":"10.1212\/WNL.0000000000007188","article-title":"Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies","volume":"92","author":"Casal-Dominguez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102993_bb0260","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00428-017-2269-x","article-title":"Anti-aminoacyl-tRNA synthetase-related myositis and dermatomyositis: clues for differential diagnosis on muscle biopsy","volume":"472","author":"Cerbelli","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.autrev.2021.102993_bb0265","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3346\/jkms.2009.24.6.1015","article-title":"Differential immunohistological features of inflammatory myopathies and dysferlinopathy","volume":"24","author":"Choi","year":"2009","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.autrev.2021.102993_bb0270","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1046\/j.1365-2990.2003.00471.x","article-title":"Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM)","volume":"29","author":"Civatte","year":"2003","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2021.102993_bb0275","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1177\/147323001003800332","article-title":"CD8\/MHC-I complex is specific but not sensitive for the diagnosis of polymyositis","volume":"38","author":"Dai","year":"2010","journal-title":"J Int Med Res"},{"key":"10.1016\/j.autrev.2021.102993_bb0280","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/PAI.0b013e31827d7f16","article-title":"Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy","volume":"21","author":"Das","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.autrev.2021.102993_bb0285","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/CND.0000000000000098","article-title":"Histopathologic findings in 5 patients with Hypomyopathic dermatomyositis: the importance of MHC-1 expression on Myofibers","volume":"17","author":"El-Dokla","year":"2015","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2021.102993_bb0290","first-page":"194","article-title":"Clinico pathological study of adult dermatomyositis: importance of muscle histology in the diagnosis. Annals of Indian academy of","volume":"18","author":"Karri","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102993_bb0295","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jocn.2019.04.002","article-title":"The clinical and histopathological features of idiopathic inflammatory myopathies with asymmetric muscle involvement","volume":"65","author":"Liu","year":"2019","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.autrev.2021.102993_bb0300","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2021.102993_bb0305","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4103\/0028-3886.125264","article-title":"Major histocompatibility complex and inflammatory cell subtype expression in inflammatory myopathies and muscular dystrophies","volume":"61","author":"Nagappa","year":"2013","journal-title":"Neurol India"},{"key":"10.1016\/j.autrev.2021.102993_bb0310","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4103\/0028-3886.84329","article-title":"Immunohistochemical differentiation of inflammatory myopathies","volume":"59","author":"Panicker","year":"2011","journal-title":"Neurol India"},{"key":"10.1016\/j.autrev.2021.102993_bb0315","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3899\/jrheum.141443","article-title":"The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis","volume":"42","author":"Pinal-Fernandez","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102993_bb0320","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102993_bb0325","doi-asserted-by":"crossref","first-page":"885","DOI":"10.6061\/clinics\/2012(08)05","article-title":"Skeletal muscle major histocompatibility complex class I and II expression differences in adult and juvenile dermatomyositis","volume":"67","author":"Shinjo","year":"2012","journal-title":"Clinics"},{"key":"10.1016\/j.autrev.2021.102993_bb0330","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clineuro.2012.07.019","article-title":"Muscle biopsy findings predictive of malignancy in rare infiltrative dermatomyositis","volume":"115","author":"Uchino","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.autrev.2021.102993_bb0335","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1046\/j.1365-4362.2002.01648.x","article-title":"Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study","volume":"41","author":"Wakata","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2021.102993_bb0340","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/jnnp.68.4.472","article-title":"Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres","volume":"68","author":"Mozaffar","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2021.102993_bb0345","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in Antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2021.102993_bb0350","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s10067-020-04979-8","article-title":"Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome","volume":"39","author":"Zhang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102993_bb0355","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/nan.12551","article-title":"Absence of sarcoplasmic myxovirus resistance protein a (MxA) expression in antisynthetase syndrome in a cohort of 194 cases","volume":"45","author":"Inoue","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2021.102993_bb0360","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00134-003-1858-0","article-title":"Critical illness polyneuromyopathy: the electrophysiological components of a complex entity","volume":"29","author":"Bednarik","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2021.102993_bb0365","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0165-5728(99)00252-0","article-title":"Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue","volume":"106","author":"De Letter","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2021.102993_bb0370","doi-asserted-by":"crossref","first-page":"R358","DOI":"10.1186\/cc2925","article-title":"Combination of histopathological and electromyographic patterns can help to evaluate functional outcome of critical ill patients with neuromuscular weakness syndromes","volume":"8","author":"Kerbaul","year":"2004","journal-title":"Crit Care"},{"key":"10.1016\/j.autrev.2021.102993_bb0375","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2013.278481","article-title":"Acute skeletal muscle wasting in critical illness","volume":"310","author":"Puthucheary","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2021.102993_bb0380","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00134-003-1894-9","article-title":"Electrophoretic determination of the myosin\/actin ratio in the diagnosis of critical illness myopathy","volume":"29","author":"Stibler","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2021.102993_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162760","article-title":"Clinicopathological features of Telbivudine-associated myopathy","volume":"11","author":"Ambang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102993_bb0390","doi-asserted-by":"crossref","first-page":"616075","DOI":"10.3389\/fneur.2020.616075","article-title":"Chloroquine and hydroxychloroquine myopathy: clinical spectrum and treatment outcomes","volume":"11","author":"Naddaf","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2021.102993_bb0395","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1590\/S0004-282X2007000100018","article-title":"Toxic myopathies: muscle biopsy features","volume":"65","author":"Scola","year":"2007","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.autrev.2021.102993_bb0400","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1002\/mus.880181312","article-title":"Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses","volume":"2","author":"Arahata","year":"1995","journal-title":"Muscle Nerve Suppl"},{"key":"10.1016\/j.autrev.2021.102993_bb0405","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0165-5728(03)00255-8","article-title":"Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study","volume":"142","author":"Confalonieri","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2021.102993_bb0410","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2990.2002.00417.x","article-title":"Muscle pathology in dysferlin deficiency","volume":"28","author":"Fanin","year":"2002","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2021.102993_bb0415","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10875-010-9474-6","article-title":"CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI","volume":"31","author":"Frisullo","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102993_bb0420","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/ane.12109","article-title":"Muscle regeneration and inflammation in patients with facioscapulohumeral muscular dystrophy","volume":"128","author":"Hauerslev","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2021.102993_bb0425","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00401-002-0654-1","article-title":"Clinical, morphological and immunological evaluation of six patients with dysferlin deficiency","volume":"105","author":"Prelle","year":"2003","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.autrev.2021.102993_bb0430","first-page":"3069","article-title":"CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy","volume":"8","author":"Yin","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.autrev.2021.102993_bb0435","first-page":"147","article-title":"Clinicopathological features of myositis and necrotizing myopathy: how to distinguish between myositis and muscular dystrophy on muscle pathology","volume":"73","author":"Saito","year":"2021","journal-title":"Brain Nerve"},{"key":"10.1016\/j.autrev.2021.102993_bb0440","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2051-5960-1-29","article-title":"Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies","volume":"1","author":"Hiniker","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.autrev.2021.102993_bb0445","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000513","article-title":"Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy","volume":"6","author":"Lim","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2021.102993_bb0450","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/978-0-387-84847-1_8","article-title":"Acute quadriplegic myopathy: an acquired \u201cmyosinopathy.\u201d","volume":"642","author":"Larsson","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.autrev.2021.102993_bb0455","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102993_bb0460","doi-asserted-by":"crossref","first-page":"102465","DOI":"10.1016\/j.autrev.2020.102465","article-title":"Anti-RNP antibodies delineate a subgroup of myositis: a systematic retrospective study on 46 patients","volume":"19","author":"Wesner","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102993_bb0465","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.semarthrit.2017.06.004","article-title":"Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement","volume":"47","author":"Albayda","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102993_bb0470","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000523","article-title":"Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy","volume":"6","author":"Mohassel","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflam"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:24:00Z","timestamp":1761600240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221002731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1568997221002731"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102993","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102993"}}